Drug Discovery World

JANUARY 31, 2024

While there has been successful development of intravitreally administered products for patients with late-stage disease, treatment options are currently limited for patients in the early or moderate stages. Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR) or age-related macular degeneration (AMD).

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

MARCH 21, 2024

It found that patients with rare kidney diseases are 28 times more likely to experience kidney failure than those with chronic kidney disease (CKD), but are less than half as likely to die before kidney failure treatment is needed. Rare kidney diseases are a group of conditions that each affect fewer than one in 2,000 people.

Disease 130

Disease Treatment Hospitals Therapies 130

KIF1A

MAY 29, 2024

Fortunately, Sloane does not currently have epilepsy, and Megan hopes this treatment will prevent it’s onset as her disease progresses. On the day of the treatment, they checked into the hospital where Sloane was administered sedation medication. The post Sloane’s 1st ASO treatment appeared first on KIF1A.

Treatment 52

Treatment Doctors Hospitals Therapies 52

Drug Discovery World

OCTOBER 30, 2023

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epcoritamab is the first licensed subcutaneous bispecific treatment option for R/R DLBCL in Great Britain.

Treatment 130

Treatment Licensing Licensing Engineering 130

Common Sense for Drug Policy Blog

OCTOBER 7, 2023

Changes in the risk of hospital admissions with injecting-related infections in and out of prison and OAT may also reflect changes in the ability to access primary and secondary health services. 2012 ; Joudrey et al., 2019 ; Treloar et al., 2014 ; Joudrey et al., 2019 ), which likely increases overdose risk more so than infection risk.

Hospitals 52

Hospitals Treatment International Drugs 52

Drug Discovery World

NOVEMBER 25, 2022

According to the partnership between the University of Birmingham and Acticor Biotech, the trial will take place in two hospitals in the UK: the Queen Elizabeth Hospital, Birmingham and the Northern General Hospital, Sheffield.

Trials 130

Trials Treatment Hospitals Laboratories 130

Drug Discovery World

JANUARY 30, 2023

The primary objectives of MOVE were to evaluate the efficacy of palovarotene in reducing new HO volume, as assessed using whole-body computed tomography. “There is a significant need for a treatment specifically developed to help manage the progression of this disease.

Treatment 130

Treatment Disease Clinical Trials Trials 130

Drug Discovery World

SEPTEMBER 16, 2022

The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases. The post UK company identifies potential new treatment for lupus appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Laboratories Hospitals Disease 130

Drug Discovery World

OCTOBER 10, 2022

A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease. . Unfortunately, no currently available treatment provides an effective solution for all patients. Official comments.

Disease 130

Disease Treatment Hospitals Therapies 130

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. million per year,” said Professor Josep Tabernero, Head of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain, and Primary Investigator for the SUNLIGHT trial. .

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Discovery World

SEPTEMBER 13, 2022

The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 by Professor Robin Jones, MD, Head of the Sarcoma Unit at The Royal Marsden Hospital, London. The post New treatment hope for patients with rare tumours appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment FDA Approval Clinical Trials Hospitals 130

Drug Discovery World

JULY 11, 2022

Pharmaceutical company Novo Nordisk has announced positive results for its prophylactic treatment targeting people living with haemophilia A or B with inhibitors. . The company’s concizumab treatment is an anti-tissue factor pathway inhibitor (TFPI)? The treatment of haemophilia is complex and no one treatment fits all, ” ?

Treatment 130

Treatment Pharmaceutical Companies Hospitals Trials 130

Drug Discovery World

FEBRUARY 9, 2023

Launched in 2020, the Oxford-based business hopes the designation will “open regulatory discussions, supplement funding, increase the viability of drug development and enable quick access to market a treatment.” SynaptixBio CEO and co-founder Dr Dan Williams said the designation was a “monumental step forward” in its bid to treat the disease.

Treatment 130

Treatment Disease Clinical Trials FDA 130

Drug Discovery World

JUNE 19, 2024

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The treatment was well tolerated and led to a significant improvement in walking distance and 40% reduction in GABAergic medications. “It

Therapies 246

Therapies Disease Hospitals Treatment 246

Drug Discovery World

JUNE 25, 2024

The paper was co-authored by analytics company Phesi and Dr Yi-Bin Chen, Director for the Blood and Marrow Transplant Program at Massachusetts General Hospital. Phesi created a digital twin for chronic graft versus host disease (cGvHD) in the primary treatment setting.

Clinical Trials 147

Clinical Trials Trials Hospitals Clinical Research 147

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 121

Treatment Immune Response Vaccine Therapies 121

Drugs.com

MARCH 21, 2024

THURSDAY, March 21, 2024 -- People with heart disease can stay healthier if they address their emotional problems as well as their physical ailments, a new study says.Treating anxiety and depression reduced ER visits and hospitalizations among.

Treatment 114

Treatment Hospitals Disease 114

Drug Discovery World

DECEMBER 16, 2022

The treatment of multiple myeloma becomes more complex with each relapse, so it is critical for frontline therapy to achieve deep treatment responses and extend survival,” said Edmond Chan, EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. Phase Ib MajesTEC-2 trial . Phase III GLOW study .

Trials 130

Trials Treatment Clinical Trials Therapies 130

Drug Discovery World

AUGUST 23, 2022

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. . Poster presented at EHA Annual Meeting, Vienna, Austria June 9 – 12, 2022. Abstract P573.

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drugs.com

MAY 20, 2024

MONDAY, May 20, 2024 -- Women treated for infertility were twice as likely as those who conceived naturally to be hospitalized with heart disease within a year of delivery, recent research shows.They are particularly likely to land in the hospital.

Treatment 69

Treatment Hospitals Disease Research 69

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes. They also found that patients’ CTAPs were dynamic and could change over time in response to treatment.

Treatment 96

Treatment RNA Hospitals Disease 96

Drug Discovery World

JULY 13, 2022

The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC). . Many people with sickle cell disease experience recurrent painful crises which can result in hospital admission.

Treatment 130

Treatment Hospitals International Disease 130

SCIENMAG: Medicine & Health

SEPTEMBER 22, 2023

A clinical trial has launched to test whether early intensive immune modulation for hospitalized COVID-19 patients with relatively mild illness is beneficial.

Clinical Trials 52

Clinical Trials Hospitals Trials Treatment 52

Drug Target Review

NOVEMBER 14, 2023

Currently, there are no satisfactory or curative treatments available. Treatment is usually directed toward symptom control and pain relief (eg, using hormones and painkillers) and/or is invasive (ie, surgical removal of the endometriotic lesions). These hormonal therapies are also not compatible with a desire to become pregnant.

Treatment 104

Treatment Disease Therapies Research 104

Common Sense for Drug Policy Blog

JULY 21, 2023

Residential Treatment Compared With Outpatient Treatment Coupled With MOUD "Residential treatment is often considered the highest intensity of treatment for individuals with OUD [ 40 ], and may by particularly important for those with unstable housing, co-morbid mental health conditions, or high medical need [ 41 ].

Treatment 52

Treatment Hospitals Research 52

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 63

Therapies Treatment FDA Approval Vaccine 63

The Pharma Data

JUNE 2, 2022

Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19. Treatment with Orencia versus placebo displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of hospital discharge. People in the Orencia group had 34.2%

Hospitals 52

Hospitals Treatment Clinical Trials Science 52

Drug Discovery World

JULY 10, 2023

A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy.

Hospitals 244

Hospitals Clinical Trials Treatment Trials 244

National Drug & Alcohol Research Centre Blog

DECEMBER 4, 2023

Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. Other changes around this time aimed at improving treatment accessibility included increased use of take-home doses and telehealth appointments.

Treatment 133

Treatment Community Pharmacies Pharmacy International 133

Drug Discovery World

MAY 28, 2024

Researchers from The University of Queensland and the Queensland Children’s Hospital (QCH) have successfully tested the first-in-class drug in mice. A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient’s blood vessels.

Immune Response 147

Immune Response Hospitals Clinical Trials Drugs 147

Drug Discovery World

JUNE 20, 2024

The treatment could be used to reverse moles, and therefore prevent cancer. The researchers from the Francis Crick Institute, UCL Great Ormond Street Institute for Child Health and Great Ormond Street Hospital for Children (GOSH) blocked the gene NRAS, which is mutated in the cells in these moles, in cells in a dish and in mice.

RNA 130

RNA Therapies Hospitals Laboratories 130

Drug Discovery World

JUNE 3, 2024

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccine 147

Vaccine Trials Clinical Trials Hospitals 147

Drug Discovery World

JUNE 27, 2024

The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. In the trial population with no prior prophylaxis treatment: Mim8 demonstrated a superior reduction in the estimated mean annualised bleeding rate (ABR) of treated bleeds by 97.1% for once-monthly treatment.

FDA Approval 147

FDA Approval Trials Treatment Hospitals 147

Drug Discovery World

NOVEMBER 22, 2022

Leading cause of hospital infections. This species is one of the leading causes of infections in hospitals, and one that is particularly good at resisting antibiotics. . During their stay in hospital the patient was treated with the antibiotic Meropenem for a suspected urinary tract infection (UTI). AMR pathogens in the gut.

Hospitals 246

Hospitals Treatment Research Drugs 246

Drug Discovery World

JUNE 4, 2024

The trial was a collaboration between UCL, UCLH, the Christie NHS Foundation Trust in Manchester, St James’s University Hospital in Leeds, University Hospital Southampton and the University of Glasgow. All of the patients in the trial were cancer-free after treatment and are still cancer-free many months later.

Trials 130

Trials Hospitals Clinical Trials Treatment 130

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. The post Unlocking the potential of mRNA for the future treatment of rare diseases appeared first on Drug Discovery World (DDW).

Disease 130

Disease Treatment Vaccine DNA 130

Drug Discovery World

JANUARY 26, 2024

AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF). Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant.

Therapies 260

Therapies Clinical Trials Hospitals Trials 260